-
Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 29c ; Offers Guidance
-
Catalyst Pharmaceuticals (CPRX) Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
-
Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 34c, Beats on Revenue; Offers FY25 Revenue Guidance
-
Catalyst Pharmaceuticals (CPRX) Announces Health Canada’s Acceptance of AGAMREE New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
-
Catalyst Pharmaceuticals (CPRX) New Drug Submission for AGAMREE Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy
-
Cantor Biotech industry report, buying value in RevGens
-
Catalyst Pharmaceutical Partners (CPRX) PT Raised to $40 at Stephens
-
Catalyst Pharmaceuticals (CPRX) Tops Q4 EPS by 38c, Beats on Revenue; Offers FY25 Revenue Guidance
-
Baird Starts Catalyst Pharmaceutical Partners (CPRX) at Outperform
-
Oppenheimer Reiterates Outperform Rating on Catalyst Pharmaceutical Partners (CPRX)
-
Catalyst Pharmaceuticals (CPRX) Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE in Japan
-
Oppenheimer on Catalyst Pharmaceutical (CPRX): 'We believe that uncertainty around this topic had kept many on the sidelines and that today's update will facilitate investor interest'
-
BofA on Catalyst Pharmaceutical (CPRX): 'Firdapse IP settlement sets favorable LOE, assuming other 2 generic filers follow suit'
-
Citi Catalyst Pharmaceutical (CPRX): 'Firdapse Patent Litigation Settlement with Teva Meaningfully Derisks LOE Overhang on Shares'
-
Catalyst Pharmaceuticals (CPRX) Announces Settlement of FIRDAPSE Patent Litigation with Teva Pharmaceuticals
-
Catalyst Pharmaceuticals (CPRX) Halted, News Pending
-
BofA Updates Endeavor List
-
Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 27c, provides guidance
-
Catalyst Pharmaceuticals (CPRX) Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan
-
Catalyst Pharmaceutical Partners (CPRX) PT Raised to $30 at H.C. Wainwright
-
Catalyst Pharmaceutical Partners (CPRX) PT Raised to $31 at Citi
-
Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 33c, Beats on Revenue; Offers FY24 Revenue Guidance
-
Eight defensive growth stocks to own right now
-
Catalyst Pharmaceuticals (CPRX) Enters Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE in Canada
-
Here are Oppenheimer’s best Smidcap ideas

